Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the following upcoming investor conferences:

  • Jefferies Healthcare Conference on Friday, June 7, 2019 at 9:30am PT (12:30pm ET) in New York, NY; and
  • Raymond James 2019 Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 5:35am (8:35am ET) in New York, NY.

All presentations will be webcast live and can be accessed via the investor section of the Aurinia website, A replay of each presentation will also be archived on the Company website following the event.

About Aurinia

Aurinia Pharmaceuticals Inc. is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations impacted by serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and dry eye syndrome (DES). The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at

Company Contact:
Glenn Schulman, PharmD, MPH
Corporate Communications

Source: Aurinia Pharmaceuticals Inc.